Grants per year
- 1 - 25 out of 1,993 results
Search results
-
Active
-
-
Prot #STML-ELA-0322: ELACESTRANT in Women and Men with CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer: An Open-Label Multicenter Phase 2 Study (ELCIN)
Gradishar, W. J. (PD/PI)
Worldwide Clinical Trials, Inc., Stemline Therapeutics, Inc.
12/6/24 → 12/6/27
Project: Research project
-
Prot #M22-003: A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
Karmali, R. (PD/PI)
11/22/24 → 11/22/27
Project: Research project
-
Prot #TP-CA-006: TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Head & Neck Squamous Cell Carcinoma (HNSCC)
Lorch, J.H.-M. (PD/PI)
11/14/24 → 11/14/27
Project: Research project
-
Prot #TV56278-ONC-10203: A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanc
Chae, Y. K. (PD/PI)
ICON Clinical Research, LLC, Teva Branded Pharmaceutical Products R&D, Inc.
11/13/24 → 11/13/27
Project: Research project
-
Prot #M24-064: AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with c-Met Over-Expressed Refractory Metastatic Colorectal Ca
Benson III, A. B. (PD/PI)
11/6/24 → 11/6/27
Project: Research project
-
Overcoming Resistance in Synovial Sarcoma to Interferon Gamma Mediated Immuno-sensitization
Pollack, S. M. (PD/PI), Chen, R. (Co-Investigator) & Obeidin, F. (Co-Investigator)
U.S. Army Medical Research and Materiel Command
11/1/24 → 10/31/27
Project: Research project
-
Prot #DS7300-189: A Phase 1b/2, Multicenter, Open-Label Study of Ifinatamab Deruxtecan (I-DXd), A B7H3 Antibody-Drug Conjugate (ADC), in Combination with Atezolizumab with or without Carboplatin as First-Line Induction or Maintenance, in Subjects with Ext
Patel, J. D. (PD/PI)
Quintiles, Inc., Daiichi Sankyo, Inc.
10/25/24 → 10/25/27
Project: Research project
-
Prot #NU 23S02: An Analysis of Nectin‐4 Expression in Soft Tissue Sarcoma
Pollack, S. M. (PD/PI)
Astellas Pharma Global Development, Inc.
10/21/24 → 4/21/26
Project: Research project
-
Prot #CNST0610C210: An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Stein, B. L. (PD/PI)
Novotech Clinical Research USA, LLC, Constellation Pharmaceuticals, Inc.
10/16/24 → 10/16/27
Project: Research project
-
Development of a novel CD73 protein degrader for melanoma immunotherapy
Zhang, B. (PD/PI) & Schiltz, G. E. (Co-Investigator)
Melanoma Research Alliance Foundation
10/4/24 → 10/3/26
Project: Research project
-
Understanding Anaphylaxis to Platinum-Based Cancer Chemotherapy and Rapid Drug Desensitization that Enables its Use in Allergic Patients
Stevens, W. (PD/PI), Berin, C. (Other), Bochner, B. S. (Other), Kircher, S. M. (Other) & Roque, D. R. (Other)
American Academy of Allergy, Asthma and Immunology
10/1/24 → 9/30/25
Project: Research project
-
Prot #CRDF-004: A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer
Benson III, A. B. (PD/PI)
Pfizer Inc., Cardiff Oncology, Inc.
10/1/24 → 10/1/25
Project: Research project
-
Prot #IMC-F106C-301: A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Chandra, S. (PD/PI)
Worldwide Clinical Trials, Inc., Immunocore Limited
9/30/24 → 9/30/27
Project: Research project
-
Single-cell tracking of the transformation of lung adenocarcinoma to small cell lung cancer
Abazeed, M. (PD/PI), Gopal, P. (Co-Investigator) & Patel, J. D. (Co-Investigator)
U.S. Army Medical Research and Materiel Command
9/30/24 → 9/29/27
Project: Research project
-
Prot #BGB-11417-203: An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination with Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia
Ma, S. (PD/PI)
9/27/24 → 9/27/27
Project: Research project
-
Prot #GS-US-595-6184: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and N
Stein, R. M. (PD/PI)
PPD Development, Gilead Sciences, Inc
9/27/24 → 9/27/27
Project: Research project
-
Prot #NU 23H05: Phase II, Single arm, Open label, study of the combination of Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following Autologous Stem Cell Transplantation (ASCT) or Chimeric Antigen Receptor (CAR) T-cell therapy in Patients
Karmali, R. (PD/PI)
9/23/24 → 9/23/27
Project: Research project
-
Development of a novel, RNA-interference-based therapeutic to treat prostate cancer
Peter, M. E. (PD/PI) & Murmann, A. E. (Co-Investigator)
NUAgo Therapeutics, Inc., National Cancer Institute
9/19/24 → 8/31/25
Project: Research project
-
Functional roles of DDX41 in the homeostasis of G quadruplexes in erythropoiesis
Ji, P. (PD/PI) & Godley, L. A. (Co-Investigator)
National Institute of Diabetes and Digestive and Kidney Diseases
9/5/24 → 8/31/29
Project: Research project
-
Clinical and Immunological Impact of Interleukin-6 Inhibition on Combination Immunotherapy Efficacy and Toxicity for Patients with Advanced Melanoma
Anouti, B. F. (PD/PI) & Patel, J. D. (PD/PI)
9/1/24 → 8/31/25
Project: Research project